MEDEZE Group Public Company Limited (SET: MEDEZE) has announced its 3Q24 consolidated financial statement through the Stock Exchange of Thailand as follows:
| Quarter | 3Q24 | 3Q23 |
| Net Profit (Loss) Million Baht |
94.69 | 69.49 |
| Earning Per Share (Baht) |
0.1200 | 0.1400 |
| % Change | 36.25 | |
| 9 Months | 9M24 | 9M23 |
| Net Profit (Loss) Million Baht |
240.47 | 184.45 |
| Earning Per Share (Baht) | 0.30 | 0.40 |
| % Change | 30.37 | |
MEDEZE reported a net profit of Baht 94.69 million in 3Q24, an increase by 36% from the same period of last year. The increase in net profit was mainly due to the increase in revenue including the company’s ability to reduce the cost of cell culture from the use of the automated mesenchymal stem cell (Quantum) incubator purchased by the Group in 2024, which can increase the number of cells in a smaller amount of times by maintaining the quality of stem cells according to the specified standards.
Moreover, MEDEZE has additional financial revenue from the return of the Government Bond that the company has invested approximately Bath 4.5 million for the 3 month period.
In the third quarter of 2024, revenue from sales and services amounted to 226.68 million baht, an increase from the same quarter of last year (YoY) of 41.09 million baht, accounting for 22.14 percent. The increase was mainly attributable to revenue from storage of stem cells collected from umbilical cord tissue segment that represent a growth of 56% YoY to 128 million baht.
The company’s gross profit margin for the three-month period was 78.83%, which was similar to the same period of last year.
Additionally, the company announced the Board of Directors resolution to approve a dividend payment at the amount of THB 0.08 per share, payable on 11 December 2024. The ex-dividend date is 26 November 2024.
